Post-Earnings Review and Highlights - Arena Pharma

LONDON, August 11, 2014 /PRNewswire/ --

Investor-Edge.com has issued complimentary earnings coverage on Arena Pharmaceuticals Inc. (NASDAQ: ARNA) as the company featured in the headlines on, August 1, 2014. Arena Pharmaceuticals Inc. reported a $56.13 million absolute decline and a $0.15 per diluted share decline in net income per share in the second quarter of 2014. Our free coverage report can be accessed at:

http://www.investor-edge.com/register

Earnings Overview  

For the second quarter of 2014, Arena Pharmaceuticals Inc. reported Research & Development (R&D) expenses of $27.03 million, versus $18.83 million in the year ago quarter. The company's general and administrative expenses increased from $8.60 million in the prior year quarter to $9.13 million during Q2 2014. During the quarter, the company gained $33.3 million on sale of available-for-sale securities in TaiGen. Arena Pharmaceuticals Inc.'s net product sales improved from $1.32 million to $3.53 million in the second quarter of 2014. The biotechnology company reported cash, cash equivalents and short-term investments available-for-sale of $219.11 million as on June 30, 2014.The free research on ARNA can be downloaded as in PDF format at:

http://www.Investor-Edge.com/ARNAFreeReport

During the reported quarter, the company's chronic weight management drug "Belviq" recorded sales of $3.5 million (including $0.4 million from the 15-day free trial voucher redemption), while Eisai, which holds marketing and distribution rights for BELVIQ for most territories worldwide sold $9.9 million worth of Belviq drug doing the same period. Further, Eisai increased its total sales representative's workforce by 200 to 600 sales representatives so as to enable them to reach approximately 92,000 doctors in the United States. In the reported quarter, Arena Pharmaceuticals Inc.'s through its wholly owned subsidiary Arena Pharmaceuticals GmbH entered into a marketing and supply agreement with Teva Pharmaceutical Industries Ltd's Israeli subsidiary to market and distribute Belviq in Israel. Sign up and read the free analyst's notes on ARNA at:

http://www.Investor-Edge.com/ARNA-11082014

Jack Lief, Arena's President and Chief Executive Officer stated that the company has witnessed encouraging advancements in the US commercialization of Belviq, with 43% quarter-over-quarter growth in estimated total prescriptions with, estimated total per week prescriptions crosses the 10,000 mark. Mr. Lief said that during the quarter the company has been able to advance in internally discovered pipeline and lorcaserin life-cycle management programs and has been able to enter into marketing and supply agreement for BELVIQ in Israel.

The biotech company reported total revenue of $12.80 million during the second quarter of 2014, compared with $68.93 million in Q2 2013. The San Diego-based company's net income stood at $7.48 million or $0.03 per share during Q2 2014, versus $40.10 million, or $0.18 per diluted share in the Q2 2013. Analyst at Bloomberg expected revenue of $9.96 million and a net loss of $22.90 billion, or $0.11 loss per share for Q2 2014.

Stock Performance  

Arena Pharmaceuticals Inc.'s shares fell 3.67% to close at $4.46 on, August 01, 2014. However, on Friday, August 08, 2014, the company's shares gained 2.09% to end at $4.39. The company's shares oscillated between $4.26 and $4.42 during the trading session. A total of 2.20 million shares were traded, which is well below its three months average volume of 5.29 million shares. Arena Pharmaceuticals Inc.'s shares have advanced 1.39% in the previous three trading sessions, while the stock has declined 13.24% in the last one month, and 24.96% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $5.41 and $6.00, respectively. Arena Pharmaceuticals Inc.' stock has a Relative Strength Index (RSI) of 34.30. Visit Investor-Edge and access the latest research on ARNA at:

http://www.Investor-Edge.com/ARNAEarningsCoverage

Sneak Peek to Corporate Insider Trading  

In the last one month, Arena Pharmaceuticals Inc. has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on ARNA is available at:

http://www.Investor-Edge.com/ARNAInsiderTrading

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge